Monocytosis (absolute monocyte count, AMC 1 3 10 9 /L) might accompany a spectrum of myeloid neoplasms, other than chronic myelomonocytic leukemia (CMML). In the current study, we examined the prevalence, laboratory and molecular correlates, and prognostic relevance of mono- /L adversely affected overall (OS; P 5 .004; HR 2.6, 95% CI 1.4-4.8) and myelofibrosis-free (MFFS; P 5 .02; HR 4.4, 95% CI 1.3-15.1) survival; during multivariable analysis, significance was borderline sustained for OS (P 5 .05) and MFFS (P 5 .06). Other independent risk factors for OS included unfavorable karyotype (P 5 .02, HR 3.39, 95% CI 1.17-9.79), older age (P < .0001, HR 3.34 95% CI 1.97-5.65), and leukocytosis 15 3 10 9 /L (P 5 .004, HR 2.04, 95% CI 1.26-3.29). In conclusion, in the current study, we encountered a higher than expected prevalence of monocytosis in patients with PV and the mutation profile and age distribution of PV patients with monocytosis is akin to those of patients with CMML and might partly contribute to their worse prognosis.
| I N T R O D U C T I O N Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN)
characterized by expansion of red cell mass and the almost invariable presence of JAK2 mutation. 1 Median survival in PV is approxi- myelofibrosis-free survival (MFFS) was adversely affected by leukocytosis, older age, JAK2 V617F allele burden, palpable splenomegaly, thrombocytosis, and mild bone marrow fibrosis, whereas leukemiafree survival (LFS) was affected by advanced age, leukocytosis, abnormal karyotype, palpable splenomegaly, and BM fibrosis. [2] [3] [4] Presence of "adverse variants/mutations" in PV, including ASXL1, SRSF2, and IDH2, has recently been shown to adversely affect OS, LFS, and MFFS. 1 The presence of absolute monocyte count (AMC) of 1 3 10 9 /L in the peripheral blood, sustained for >3 months, along with bone marrow dysplasia defines chronic myelomonocytic leukemia (CMML), a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes (MDS) and MPN. 5 However, absolute monocytosis can also been seen in other myeloid neoplasms, including MDS and MPN, 6 and its presence has previously been shown to indicate a worse prognosis in patients with lymphoid neoplasms, 7 primary . Among informative cases, palpable splenomegaly was present in 21%, pruritus in 71%, and erythromelalgia in 5%.
| MATERIAL AND M ETHODS
Thrombosis history at diagnosis was documented in 30% of the patients and 20% experienced thrombotic events after diagnosis.
Mutational frequencies included, JAK2 (n evaluable 5 226) 99%, TET2
(n evaluable 5 86) 22%, ASXL1 (n evaluable 5 86) 8%, and SRSF2 (n evaluable 5 86) 3%, respectively. Information on cytogenetic studies was available in 161 patients and karyotype was normal in 82%. After a median follow-up of 77 months, 83 (31%) deaths, 21 (8%) fibrotic progressions, 9 (3%) leukemic, and 0 (0%) myelodysplastic transformations were documented. and SRSF2 mutations (P 5 .0002): a borderline correlation was noted with male sex (P 5 .09) and absence of pruritus (P 5 .05).
| Survival analysis
In univariate analysis, OS was affected by AMC as a continuous variable (P 5 .048) and both AMC 1 3 10 9 /L (P 5 .01, HR 1.88, 95% CI 1.53-3.07, Figure 1A ) and AMC 1. Figure   2C ); thrombosis-free survival (TFS) was not affected (P 5 .5, data not shown). In contrast, AMC 1 3 10 9 /L did not appear to significantly affect MFFS (P 5 .9, Figure 1B ) or LFS (P 5 .6, Figure 1C ).
| DISCUSSION
Monocytosis (1 3 10 9 /L) is a common finding in hematological malignancies 6 and has been shown to indicate a worse prognosis in patients with lymphoid 7, 14 and certain myeloid neoplasms. 8, 15 The prevalence and clinical significance of monocytosis has not been previously 
